LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

97.23 0.21

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

96.71

Massimo

98.76

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	13.723 50.102
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 368M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+11.52% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	362M 19B
Apertura precedente	97.02
Chiusura precedente	97.23

Notizie sul Sentiment di mercato

By Acuity

25%

75%

39 / 344 Classifica in Healthcare

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mag 2026, 21:33 UTC

Utili

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mag 2026, 21:00 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mag 2026, 20:18 UTC

Utili

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mag 2026, 23:49 UTC

Discorsi di Mercato

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mag 2026, 23:39 UTC

Discorsi di Mercato

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 mag 2026, 23:08 UTC

Discorsi di Mercato

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mag 2026, 22:21 UTC

Discorsi di Mercato

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mag 2026, 21:29 UTC

Azioni calde

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mag 2026, 21:08 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mag 2026, 21:02 UTC

Utili

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mag 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mag 2026, 20:55 UTC

Utili

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 mag 2026, 20:48 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mag 2026, 20:45 UTC

Utili

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mag 2026, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 mag 2026, 20:32 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mag 2026, 20:30 UTC

Utili

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mag 2026, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mag 2026, 20:22 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:16 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mag 2026, 20:13 UTC

Utili

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

11.52% in crescita

Previsioni per 12 mesi

Media 108.29 USD 11.52%

Alto 135 USD

Basso 75 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

39 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation